From John Money to Modern Gender Clinics: An Insider Speaks - Dr. Quentin Van Meter (#28)
A paediatric endocrinologist who trained at Johns Hopkins alongside John Money spent four decades watching gender medicine grow from improvised experiments into global institutional consensus — and spent much of that time pushing back. Dr Quentin Van Meter's insider account resonates closely with what the Cass Review found in Britain: a field shaped by ideology rather than evidence, professional bodies that suppressed dissent, and children placed on medical pathways on the basis of claims that do not survive rigorous examination. His testimony provides the American chapter of a story the NHS is still reckoning with.
For British listeners who followed the Cass Review's methodical audit of the evidence underpinning NHS gender services, Dr Quentin Van Meter offers something Hilary Cass's independent team could not: a first-hand account of how that evidence base was assembled — and why it was always so thin. A paediatric endocrinologist with four decades of clinical experience, Van Meter was present at Johns Hopkins during John Money's career, close enough to observe not only Money's theories but the methods and practices behind them. He speaks about Money not as a historical figure known from textbooks but as someone whose conduct he witnessed directly. Van Meter treated his first gender-distressed child in 1993, when clinical guidelines did not yet exist and practitioners were operating largely on improvisation and ideology. What follows in his account is the story of a specialism that accumulated institutional weight without ever establishing the rigorous evidence base that any intervention in a child's hormonal development ought to require. He describes the World Professional Association for Transgender Health as having functioned less as a scientific standards body than as an advocacy organisation — one whose bibliography, in his assessment, does not withstand serious scrutiny. The clinical claims he advances will be recognisable to anyone who studied the Cass Review carefully. His contention that puberty blockers carry a risk of long-term cognitive harm mirrors concerns that NHS clinicians had raised internally for years before they were taken seriously. His observation that the overwhelming majority of children placed on blockers then proceed to cross-sex hormones challenges the argument that blockers are a reversible pause that preserves options. That framing was used to justify widespread prescribing at Tavistock's Gender Identity Development Service, and the Cass Review found the evidence supporting it to be inadequate. Van Meter's account, drawn from clinical practice rather than retrospective review, reaches the same destination by a different route. His decision to leave the American Academy of Pediatrics after nearly four decades — following what he describes as the organisation adopting a fabricated transgender health policy — places him alongside British clinicians who raised concerns about the Tavistock and found the institutional response was marginalisation rather than inquiry. The pattern is consistent: professional bodies subordinating clinical judgement to ideological consensus, and individuals who dissented paying a professional price for doing so. The conversation broadens into how an entire field can travel so far from the principles of evidence and informed consent when patient sympathy and political momentum converge. Van Meter's conclusion — that no biological basis has been established for the idea that a person can be born with a gender identity that conflicts with their sex — is one he reaches from a career at the clinical coalface of endocrinology. For anyone in Britain still asking how NHS gender medicine arrived where it did, this is the American context that helps explain the full picture.
